Tempus AI agreed to acquire Personalis for about $1.5B to expand its AI-enabled precision medicine capabilities into Personalis’ oncology test/portfolio. The deal is positioned as a strategic step to bring Tempus’s cancer test into Personalis’ oncology offerings, suggesting growth optionality for its precision oncology platform.
Tempus AI agreed to acquire Personalis for about $1.5B to expand its AI-enabled precision medicine capabilities into Personalis’ oncology test/portfolio. The deal is positioned as a strategic step to bring Tempus’s cancer test into Personalis’ oncology offerings, suggesting growth optionality for its precision oncology platform.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
